Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 6/2016

01-06-2016 | Original paper

A prospective study of oral contraceptive use and colorectal adenomas

Authors: Brittany M. Charlton, Edward Giovannucci, Charles S. Fuchs, Andrew T. Chan, Jung Eun Lee, Yin Cao, Stacey A. Missmer, Bernard A. Rosner, Susan E. Hankinson, Walter Willett, Kana Wu, Karin B. Michels

Published in: Cancer Causes & Control | Issue 6/2016

Login to get access

Abstract

Purpose

The influence of reproductive factors on colorectal cancer, including oral contraceptive (OC) use, has been examined, but less research is available on OC use and adenomas.

Methods

Participants of the Nurses’ Health Study who had a lower bowel endoscopy between 1986 (when endoscopies were first assessed) and 2008 were included in this study. Multivariable logistic regression models for clustered data were used to estimate odds ratios and 95 % confidence intervals [OR (95 % CIs)].

Results

Among 73,058 participants, 51 % (n = 37,382) reported ever using OCs. Ever OC use was associated with a slight increase in non-advanced adenomas [OR 1.11, 95 % CI (1.02, 1.21)] but not with any other endpoints. Duration of OC use was not associated with adenomas, but longer times since last OC use were associated with increased odds of adenomas [e.g., compared to never use, 15+ years since last use: OR 1.17 (1.07, 1.27)]. Shorter times since last OC use were inversely associated [e.g., ≤4 years since last use: OR 0.74 (0.65, 0.84)].

Conclusions

We observed a modest borderline increase in risk of colorectal adenomas with any prior OC use. Additionally, more recent OC use may decrease risk, while exposure in the distant past may modestly increase risk of adenomas.
Appendix
Available only for authorised users
Literature
1.
2.
La Vecchia C, Franceschi S (1991) Reproductive factors and colorectal cancer. Cancer Causes Control 2(3):193–200CrossRefPubMed
3.
Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, Gapstur SM, Folsom AR (1994) Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control 5(1):38–52CrossRefPubMed
4.
Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR (2007) Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 18(7):723–733. doi:10.​1007/​s10552-007-9015-7 CrossRefPubMed
5.
Fernandez E, La Vecchia C, D’Avanzo B, Franceschi S, Negri E, Parazzini F (1996) Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer 73(11):1431–1435CrossRefPubMedPubMedCentral
6.
Fernandez E, La Vecchia C, Franceschi S, Braga C, Talamini R, Negri E, Parazzini F (1998) Oral contraceptive use and risk of colorectal cancer. Epidemiology 9(3):295–300CrossRefPubMed
7.
Furner SE, Davis FG, Nelson RL, Haenszel W (1989) A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 49(17):4936–4940PubMed
8.
9.
10.
Kabat GC, Miller AB, Rohan TE (2008) Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer 122(3):643–646. doi:10.​1002/​ijc.​23079 CrossRefPubMed
11.
Kampman E, Bijl AJ, Kok C, van’t Veer P (1994) Reproductive and hormonal factors in male and female colon cancer. Eur J Cancer Prev 3(4):329–336CrossRefPubMed
12.
Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S (1997) Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 8(2):146–158CrossRefPubMed
13.
Levi F, Pasche C, Lucchini F, La Vecchia C (2003) Oral contraceptives and colorectal cancer. Dig Liver Dis 35(2):85–87CrossRefPubMed
14.
Lin J, Zhang SM, Cook NR, Manson JE, Buring JE, Lee IM (2007) Oral contraceptives, reproductive factors, and risk of colorectal cancer among women in a prospective cohort study. Am J Epidemiol 165(7):794–801. doi:10.​1093/​aje/​kwk068 CrossRefPubMed
15.
Martinez ME, Grodstein F, Giovannucci E, Colditz GA, Speizer FE, Hennekens C, Rosner B, Willett WC, Stampfer MJ (1997) A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 6(1):1–5PubMed
16.
17.
Potter JD, McMichael AJ (1983) Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 71(4):703–709PubMed
18.
Talamini R, Franceschi S, Dal Maso L, Negri E, Conti E, Filiberti R, Montella M, Nanni O, La Vecchia C (1998) The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. Eur J Cancer 34(7):1070–1076CrossRefPubMed
19.
Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF Jr (1997) Reproductive factors, oral contraceptive use, and risk of colorectal cancer. Epidemiology 8(1):75–79CrossRefPubMed
20.
van Wayenburg CA, van der Schouw YT, van Noord PA, Peeters PH (2000) Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort. Epidemiology 11(3):304–308CrossRefPubMed
21.
22.
Wu-Williams AH, Lee M, Whittemore AS, Gallagher RP, Jiao DA, Zheng S, Zhou L, Wang XH, Chen K, Jung D et al (1991) Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 51(9):2307–2311PubMed
23.
Jacobson JS, Neugut AI, Garbowski GC, Ahsan H, Waye JD, Treat MR, Forde KA (1995) Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Cancer Causes Control 6(6):513–518CrossRefPubMed
24.
Peipins LA, Newman B, Sandler RS (1997) Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 6(9):671–675PubMed
25.
Platz EA, Martinez ME, Grodstein F, Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci E (1997) Parity and other reproductive factors and risk of adenomatous polyps of the distal colorectum (United States). Cancer Causes Control 8(6):894–903CrossRefPubMed
26.
Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128(9):705–712CrossRefPubMed
27.
28.
Hebert-Croteau N (1998) A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 7(8):653–659PubMed
29.
Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J, Grambsch P, Louis TA (1996) Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 5(10):779–784PubMed
30.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
31.
Wolf LA, Terry PD, Potter JD, Bostick RM (2007) Do factors related to endogenous and exogenous estrogens modify the relationship between obesity and risk of colorectal adenomas in women? Cancer Epidemiol Biomarkers Prev 16(4):676–683. doi:10.​1158/​1055-9965.​EPI-06-0883 CrossRefPubMed
32.
Woodson K, Lanza E, Tangrea JA, Albert PS, Slattery M, Pinsky J, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin A (2001) Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst 93(23):1799–1805CrossRefPubMed
33.
McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201–1207PubMed
34.
35.
Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C, Peris C, Fiorucci GC, Sismondi P (1993) Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 7(4):251–258CrossRefPubMed
36.
37.
Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11(7):622–629PubMed
38.
Belanger CF, Hennekens CH, Rosner B, Speizer FE (1978) The nurses’ health study. Am J Nurs 78(6):1039–1040PubMed
39.
Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC (1990) Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1(6):466–473CrossRefPubMed
40.
Therneau TM, Hamilton SA (1997) rhDNase as an example of recurrent event analysis. Stat Med 16(18):2029–2047CrossRefPubMed
41.
Colin EM, Van Den Bemd GJ, Van Aken M, Christakos S, De Jonge HR, Deluca HF, Prahl JM, Birkenhager JC, Buurman CJ, Pols HA, Van Leeuwen JP (1999) Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res 14(1):57–64. doi:10.​1359/​jbmr.​1999.​14.​1.​57 CrossRefPubMed
42.
Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540. doi:10.​1038/​ng0894-536 CrossRefPubMed
43.
Lointier P, Wildrick DM, Boman BM (1992) The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 12(4):1327–1330PubMed
44.
45.
Oshima CT, Wonraht DR, Catarino RM, Mattos D, Forones NM (1999) Estrogen and progesterone receptors in gastric and colorectal cancer. Hepatogastroenterology 46(30):3155–3158PubMed
46.
Schwartz B, Smirnoff P, Shany S, Liel Y (2000) Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol Cell Biochem 203(1–2):87–93CrossRefPubMed
47.
Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14(1):75–84CrossRefPubMed
48.
Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B (1999) The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 11(6):255–264PubMed
49.
50.
Piper JM, Kennedy DL (1987) Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 16(2):215–221CrossRefPubMed
Metadata
Title
A prospective study of oral contraceptive use and colorectal adenomas
Authors
Brittany M. Charlton
Edward Giovannucci
Charles S. Fuchs
Andrew T. Chan
Jung Eun Lee
Yin Cao
Stacey A. Missmer
Bernard A. Rosner
Susan E. Hankinson
Walter Willett
Kana Wu
Karin B. Michels
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 6/2016
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-016-0752-3

Other articles of this Issue 6/2016

Cancer Causes & Control 6/2016 Go to the issue

Original paper

Predictors of biospecimen donation in the Black Women’s Health Study

Original paper

Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors

Brief report

Breast and cervical cancer screening among Asian subgroups in the USA: estimates from the National Health Interview Survey, 2008, 2010, and 2013

Commentary

50 % Response rates: half-empty, or half-full?

Original Paper

Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study

Original paper

Underutilization of gene expression profiling for early-stage breast cancer in California
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits